GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Epigenomics AG (OTCPK:EPGNF) » Definitions » Total Liabilities

Epigenomics AG (Epigenomics AG) Total Liabilities : $2.50 Mil (As of Jun. 2023)


View and export this data going back to . Start your Free Trial

What is Epigenomics AG Total Liabilities?

Epigenomics AG's Total Liabilities for the quarter that ended in Jun. 2023 was $2.50 Mil.

Epigenomics AG's quarterly Total Liabilities increased from Dec. 2022 ($6.02 Mil) to Mar. 2023 ($7.00 Mil) but then declined from Mar. 2023 ($7.00 Mil) to Jun. 2023 ($2.50 Mil).

Epigenomics AG's annual Total Liabilities declined from Dec. 2020 ($3.57 Mil) to Dec. 2021 ($2.87 Mil) but then increased from Dec. 2021 ($2.87 Mil) to Dec. 2022 ($6.02 Mil).


Epigenomics AG Total Liabilities Historical Data

The historical data trend for Epigenomics AG's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Epigenomics AG Total Liabilities Chart

Epigenomics AG Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.66 4.84 3.57 2.87 6.02

Epigenomics AG Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.18 4.99 6.02 7.00 2.50

Epigenomics AG Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Epigenomics AG's Total Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=5.375+(0.548+0.094
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=6.02

Total Liabilities=Total Assets (A: Dec. 2022 )-Total Equity (A: Dec. 2022 )
=16.792-10.775
=6.02

Epigenomics AG's Total Liabilities for the quarter that ended in Jun. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.329+(0.134+0.038
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=2.50

Total Liabilities=Total Assets (Q: Jun. 2023 )-Total Equity (Q: Jun. 2023 )
=4.569-2.068
=2.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Epigenomics AG Total Liabilities Related Terms

Thank you for viewing the detailed overview of Epigenomics AG's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Epigenomics AG (Epigenomics AG) Business Description

Traded in Other Exchanges
Address
Geneststrasse 5, Berlin, BB, DEU, 10829
Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.

Epigenomics AG (Epigenomics AG) Headlines